Genetic mutations linked to breast cancer, colon cancer, melanoma, and other cancers already have led to diagnostic tests that can point to the most effective intervention. Recent discoveries in cancer genomics have helped to identify several treatments that work by targeting cancer cells with a specific genetic change, such as Gleevec®, a drug for chronic myeloid leukemia and gastrointestinal stromal tumors, and Herceptin®, a drug for one form of breast cancer. These successful developments support further examination of the molecular origins of cancer to more quickly develop new tools to diagnose, treat, and prevent cancer.
In the TCGA Pilot Project, a Human Cancer Biospecimen Core Resource will support the collection, processing, and distribution of cancerous and healthy, control tissue samples to Cancer Genome Characterization Centers and Genome Sequencing Centers. The genes and other genomic targets identified will be sequenced by the Cancer Genome Sequencing Centers using high-throughput methods similar to those employed in the Human Genome Project. The Cancer Genome Atlas Pilot Project seeks to identify genetic mutations in the DNA code that are specifically associated with the type of cancer being sequenced. In addition, the Cancer Genome Characterization Centers will work to identify other types of larger-scale genomic changes, such as copy number changes and/or chromosomal translocations, that contribute to cancer development and/or progression.
These data from TCGA Centers will be deposited in public databases supported by NCI's cancer Biomedical Informatics Grid (caBIG
Source:NIH/National Human Genome Research Institute